In vivo and in vitro immunological changes induced by a short course of grass allergy immunotherapy tablets

Journal of Investigational Allergology and Clinical Immunology

Volumn 20, Issue 6, 2010, Pages 454-462

  Panizo, C ^a   Cimarra, M ^b   Gonzalez Mancebo E ^c   Vega, A ^d   Senent, C ^e   Martin S ^f  

^a HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e HOSPITAL VIRGEN DE LA SALUD   (Spain)

^f ALK ABELLÓ   (Denmark)

Author keywords

Grass allergy immunotherapy tablet; Grass pollen allergy; Immunological changes; Sublingual immunotherapy

Indexed keywords

GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PHLEUM PRATENSE; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SKIN TEST; TABLET; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ADULT; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MALE; POACEAE; TABLETS;

EID: 78650125642     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet L P, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci 0, Kaliner M.A., Kim Y.Y, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe K F, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano L, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp J P, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru M P, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86: 8-160.
2. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025-34.
3. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Rivas M F, Ribel M, Durham SR. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118:434-40.
4. Dahl R, Kapp A, Colombo G, de Monchy JG, Rak S, Emminger W, Riis B, Grønager PM, Durham SR. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefi t with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121:512-8.
5. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009;123:167-73.
6. Durham S, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007;62:954-7.
7. Rak S, Yang WH, Pedersen MR, Durham S. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res. 2007;16(2):191-201.
8. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61(2):185-90.
9. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802-9.
10. ®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis-a Northern European perspective. Clin Exp Allergy. 2007;37:772-9.
11. ® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe. Respir Med. 2007;101:1885-94.
12. Petersen AB, Gudmann P, Milvang-Grønager P, Mørkeberg R, Bøgestrand S, Lin-neberg A, Johansen N. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem. 2004;37:882-92.
13. Jimeno L, Carreira J, Lombardero M. Obtention of monoclonal antibodies against human IgG4 using two different immunization strategies: development of a biotin-based ELISA for IgG4 quantitation. Int Arch Allergy Appl Immunol. 1990;92:175-82.
14. Martín S, Cuesta P, Rico P, Cortés C. A computer program based on parallel line assay for analysis of skin tests Allergy. 1997;52:97-100.
15. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007;62(8):958-61.
16. Emminger W, Dahl R, Kapp A, Colombo G, de Monchi J, Rak S, Denlow B, Durham S. Continuous clinical efficacy and progressive immunological effect of long-term specific immunotherapy with the ALK grass allergen tablet: Findings from a 3-yr randomised adult trial. Allergy. 2008;63(Suppl 88):614.
17. Durham SR, Dahl R, Kapp A, Colombo G, de Monchi J, Rak S, Riis B, Emminger W. Sustained, disease-modifying effect of grass allergen tablet immunotherapy 1 year after completion of treatment Allergy. 2009;64(Suppl 90):Abstract 333.
18. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915-22.
19. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Infl uence of grass pollen immunotherapy on cellular infi ltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993;92:644-51.
20. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-75.
21. Durham SR, Varney VA, Gaga M, Jacobson MR, Varga EM, Frew AJ, Kay AB. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy. 1999;29:1490-6.
22. Malling HJ, Lund L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol.2006;16:162-8.
23. W. Aberer, T. Hawranek, N. Reider, C. Schuster, G. Sturm, B. Kränk e. Immunoglobulin E and G antibody profi les to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol. 2007;17(3):131-6.
24. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol. 2004;4:313-8.
25. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol. 2007:120:S25-S85.
26. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 1973;52:472-82.
27. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982;70:261-71.
28. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Compari-son between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82:439-46.
29. Parker WA Jr, Whisman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:667-77.
30. Ljorring C, Frew AJ, Durham SR, Jacobsen L, Johansen N, Jarsen J.N Ipsen H. In-duction of a competitive non-IgE antibody response by specific immunotherapy is related to clinical efficacy. J Allergy Clin Immunol. 2006;117:S264.
31. Parker WA Jr, Whisman BA, Apaliski SJ, Reid MJ. The relationships between late cutaneous responses and specific antibody responses with outcome of immunotherapy for seasonal allergic rhinitis. J Allergy Clin Immunol. 1989;84:667-77.
32. Rossi RE, Monasterolo G, Coco, G Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine. 2007; 25:957-64.
33. Kleine-Tebbe, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tab-let for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006; 61:181-84.
34. Ibáñez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B, Bufe A. Safety of specific sublingual immunotherapy with SQ standardised grass allergen tablets in children. Pediatr. Allergy Immunol. 2007;18:516-22.
35. Calderón M, Essendrop M. Specific immunotherapy with high dose SQ-standardised grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol. 2006;16(6):338-44.
36. Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-a phase 1 study. Allergy. 2006;61:1173-6.